Patents by Inventor Xiaozhang Zheng

Xiaozhang Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRAK degraders and uses thereof
    Patent number: 12091411
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 31, 2023
    Date of Patent: September 17, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nello Mainolfi, Chris De Savi, Matthew M. Weiss, Xiao Zhu, Xiaozhang Zheng, Bruce C. Follows
  • STAT DEGRADERS AND USES THEREOF
    Publication number: 20240293423
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 7, 2021
    Publication date: September 5, 2024
    Inventors: Bin YANG, Xiaozhang ZHENG, Xiao ZHU
  • Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
    Patent number: 12071440
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Grant
    Filed: March 21, 2023
    Date of Patent: August 27, 2024
    Assignee: Novo Nordisk Health Care AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • Treating sickle cell disease with a pyruvate kinase R activating compound
    Patent number: 12053458
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: August 6, 2024
    Assignee: Novo Nordisk Health Care AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Bingsong Han, Lorna Mitchell, David Richard, Zhongguo Wang, Tatiana Shelekhin, Chase C. Smith, Xiaozhang Zheng
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20240239777
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 19, 2023
    Publication date: July 18, 2024
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang, Xiaozhang Zheng
  • CDK2 INHIBITORS AND USES THEREOF
    Publication number: 20240174665
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 21, 2023
    Publication date: May 30, 2024
    Inventors: Philip COLLIER, Xiaozhang ZHENG, Xiao ZHU, Melissa FORD, Matthew M. WEISS, Robert AVERSA, Kiran Vijayakumari MAHASENAN, Yi ZHANG
  • CDK2 DEGRADERS AND USES THEREOF
    Publication number: 20240173419
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 21, 2023
    Publication date: May 30, 2024
    Inventors: Philip COLLIER, Xiaozhang ZHENG, Xiao ZHU, Melissa FORD, Matthew M. WEISS, Robert AVERSA, Lewis Dale PENNINGTON, Eamon COMER, Kiran Vijayakumari MAHASENAN, Yi ZHANG
  • Treating sickle cell disease with a pyruvate kinase R activating compound
    Patent number: 11980611
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: May 14, 2024
    Assignee: Novo Nordisk Health Care AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • MDM2 degraders and uses thereof
    Patent number: 11932624
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 10, 2022
    Date of Patent: March 19, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nan Ji, Matthew M. Weiss, Xiaozhang Zheng, Xiao Zhu
  • PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
    Publication number: 20240083901
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Application
    Filed: March 21, 2023
    Publication date: March 14, 2024
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. LANCIA, JR., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
  • Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
    Patent number: 11919839
    Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 5, 2024
    Assignee: VALO HEALTH, INC.
    Inventors: Kenneth W. Bair, Nicholas Barczak, Bingsong Han, David R. Lancia, Jr., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Mary-Margaret Zablocki, Xiaozhang Zheng
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20240059674
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: May 10, 2023
    Publication date: February 22, 2024
    Inventors: Nello MAINOLFI, Nan Ji, Mathew M. Weiss, Xiaozhang Zheng, Yi Zhang, Paul R. Fleming
  • 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11891365
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: February 6, 2024
    Assignee: VALO HEALTH, INC.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Heather Davis, Aleksandra Rudnitskaya, David R. Lancia, Jr., Kenneth W. Bair, David S. Millan, Matthew W. Martin
  • MDM2 DEGRADERS AND USES THEREOF
    Publication number: 20240025878
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 10, 2022
    Publication date: January 25, 2024
    Inventors: Nan JI, Matthew M. WEISS, Xiaozhang ZHENG, Xiao ZHU
  • STAT DEGRADERS AND USES THEREOF
    Publication number: 20240016942
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 17, 2021
    Publication date: January 18, 2024
    Inventors: Nan JI, Bin YANG, Xiaozhang ZHENG, Xiao ZHU
  • DOUBLE DEGRADERS AND USES THEREOF
    Publication number: 20230416242
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 21, 2021
    Publication date: December 28, 2023
    Inventors: Matthew M. WEISS, Xiaozhang ZHENG, Xiao ZHU
  • 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS
    Publication number: 20230414585
    Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
    Type: Application
    Filed: June 29, 2023
    Publication date: December 28, 2023
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Mary-Margaret Zablocki
  • CRYSTALLINE FORMS OF IRAK DEGRADERS
    Publication number: 20230406866
    Abstract: The present disclosure relates generally to various forms, salts and compositions of compounds useful for the modulation of one or more interleukin-1 receptor-associated kinases (“IRAK”) via ubiquitination and/or degradation and uses of the same in the treatment various diseases.
    Type: Application
    Filed: May 18, 2023
    Publication date: December 21, 2023
    Inventors: Xiaozhang ZHENG, Don CORSON
  • [6,6] FUSED BICYCLIC HDAC8 INHIBITORS
    Publication number: 20230406830
    Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2?, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
    Type: Application
    Filed: January 13, 2023
    Publication date: December 21, 2023
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Jennifer R. Downing, Mary-Margaret Zablocki, Bingsong Han, Nicholas Barczak, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, JR., Kenneth W. Bair
  • TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND
    Publication number: 20230381151
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Application
    Filed: December 22, 2022
    Publication date: November 30, 2023
    Inventors: Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. Lancia, JR., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG